{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:45:06Z","timestamp":1795059906998,"version":"4.10.2"},"reference-count":335,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41582-025-01163-x","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:41:21Z","timestamp":1764776481000},"page":"90-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Characteristics and mechanisms of cognitive impairment in Parkinson disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-2861","authenticated-orcid":false,"given":"Panteleimon","family":"Oikonomou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh H.","family":"Akhoundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Olfati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-3445","authenticated-orcid":false,"given":"Irene","family":"Litvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public. Health 7, e105\u2013e125 (2022).","journal-title":"Lancet Public. Health"},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2666-7568(24)00094-1","volume":"5","author":"J Zhu","year":"2024","unstructured":"Zhu, J. et al. Temporal trends in the prevalence of Parkinson\u2019s disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev. 5, e464\u2013e479 (2024).","journal-title":"Lancet Healthy Longev."},{"key":"1163_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras, C. et al. Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinsons Dis. 4, 21 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su, D. et al. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388, e080952 (2025).","journal-title":"BMJ"},{"key":"1163_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland, D. et al. Parkinson disease-associated cognitive impairment. Nat. Rev. Dis. Primers 7, 47 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1163_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209699","volume":"103","author":"J Gallagher","year":"2024","unstructured":"Gallagher, J. et al. Long-term dementia risk in Parkinson disease. Neurology 103, e209699 (2024).","journal-title":"Neurology"},{"key":"1163_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.91","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 509 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"1163_CR8","doi-asserted-by":"publisher","first-page":"e2045","DOI":"10.1212\/WNL.0000000000006576","volume":"91","author":"D Backstrom","year":"2018","unstructured":"Backstrom, D. et al. Early predictors of mortality in parkinsonism and Parkinson disease: a population-based study. Neurology 91, e2045\u2013e2056 (2018).","journal-title":"Neurology"},{"key":"1163_CR9","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/mds.23823","volume":"26","author":"I Litvan","year":"2011","unstructured":"Litvan, I. et al. MDS Task Force on mild cognitive impairment in Parkinson\u2019s disease: critical review of PD-MCI. Mov. Disord. 26, 1814\u20131824 (2011).","journal-title":"Mov. Disord."},{"key":"1163_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0055-3","volume":"4","author":"JG Goldman","year":"2018","unstructured":"Goldman, J. G. et al. Cognitive impairment in Parkinson\u2019s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. NPJ Parkinsons Dis. 4, 19 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/bs11050074","volume":"11","author":"P Gonzalez-Latapi","year":"2021","unstructured":"Gonzalez-Latapi, P., Bayram, E., Litvan, I. & Marras, C. Cognitive impairment in Parkinson\u2019s disease: epidemiology, clinical profile, protective and risk factors. Behav. Sci. (Basel) 11, 74 (2021).","journal-title":"Behav. Sci. (Basel)"},{"key":"1163_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/mds.27670","volume":"34","author":"RB Postuma","year":"2019","unstructured":"Postuma, R. B. & Berg, D. Prodromal Parkinson\u2019s disease: the decade past, the decade to come. Mov. Disord. 34, 665\u2013675 (2019).","journal-title":"Mov. Disord."},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.parkreldis.2020.11.013","volume":"82","author":"CY Chua","year":"2021","unstructured":"Chua, C. Y. et al. Subjective cognitive complaints in early Parkinson\u2019s disease patients with normal cognition are associated with affective symptoms. Parkinsonism Relat. Disord. 82, 24\u201328 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/mds.29649","volume":"39","author":"M Siciliano","year":"2024","unstructured":"Siciliano, M., Tessitore, A., Morgante, F., Goldman, J. G. & Ricciardi, L. Subjective cognitive complaints in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 39, 17\u201328 (2024).","journal-title":"Mov. Disord."},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27, 349\u2013356 (2012).","journal-title":"Mov. Disord."},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/mds.27002","volume":"32","author":"J Hoogland","year":"2017","unstructured":"Hoogland, J. et al. Mild cognitive impairment as a risk factor for Parkinson\u2019s disease dementia. Mov. Disord. 32, 1056\u20131065 (2017).","journal-title":"Mov. Disord."},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mds.27617","volume":"34","author":"J Hoogland","year":"2019","unstructured":"Hoogland, J. et al. Risk of Parkinson\u2019s disease dementia related to level I MDS PD-MCI. Mov. Disord. 34, 430\u2013435 (2019).","journal-title":"Mov. Disord."},{"key":"1163_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0000000000003634","volume":"88","author":"KF Pedersen","year":"2017","unstructured":"Pedersen, K. F., Larsen, J. P., Tysnes, O. B. & Alves, G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology 88, 767\u2013774 (2017).","journal-title":"Neurology"},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","volume":"84","author":"CH Williams-Gray","year":"2013","unstructured":"Williams-Gray, C. H. et al. The CamPaIGN study of Parkinson\u2019s disease: 10-year outlook in an incident population-based cohort. J. Neurol. Neurosurg. Psychiatry 84, 1258\u20131264 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837\u2013844 (2008).","journal-title":"Mov. Disord."},{"key":"1163_CR21","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/mds.29918","volume":"39","author":"LL Gibson","year":"2024","unstructured":"Gibson, L. L. et al. Risk of dementia in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 39, 1697\u20131709 (2024).","journal-title":"Mov. Disord."},{"key":"1163_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2086","volume":"11","author":"P Oikonomou","year":"2021","unstructured":"Oikonomou, P. et al. Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson\u2019s disease. Brain Behav. 11, e02086 (2021).","journal-title":"Brain Behav."},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00415-020-09757-9","volume":"268","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. Predictors of cognitive impairment in Parkinson\u2019s disease: a systematic review and meta-analysis of prospective cohort studies. J. Neurol. 268, 2713\u20132722 (2021).","journal-title":"J. Neurol."},{"key":"1163_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209656","volume":"103","author":"DG Coughlin","year":"2024","unstructured":"Coughlin, D. G. et al. Association of CSF \u03b1-synuclein seeding amplification assay results with clinical features of possible and probable dementia with lewy bodies. Neurology 103, e209656 (2024).","journal-title":"Neurology"},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/brain\/awz311","volume":"143","author":"E Matar","year":"2020","unstructured":"Matar, E., Shine, J. M., Halliday, G. M. & Lewis, S. J. G. Cognitive fluctuations in lewy body dementia: towards a pathophysiological framework. Brain 143, 31\u201346 (2020).","journal-title":"Brain"},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith, I. G. et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94, 743\u2013755 (2020).","journal-title":"Neurology"},{"key":"1163_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14450","volume":"21","author":"KA Wyman-Chick","year":"2025","unstructured":"Wyman-Chick, K. A. et al. Neuropsychological test performance in mild cognitive impairment with Lewy bodies: a systematic review and meta-analysis. Alzheimers Dement. 21, e14450 (2025).","journal-title":"Alzheimers Dement."},{"key":"1163_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200380","volume":"15","author":"KA Wyman-Chick","year":"2025","unstructured":"Wyman-Chick, K. A. et al. Distinguishing prodromal dementia with Lewy bodies from prodromal Alzheimer disease: a longitudinal study. Neurol. Clin. Pract. 15, e200380 (2025).","journal-title":"Neurol. Clin. Pract."},{"key":"1163_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-024-02704-y","volume":"36","author":"MI Burgio","year":"2024","unstructured":"Burgio, M. I. et al. Markers for the detection of Lewy body disease versus Alzheimer\u2019s disease in mild cognitive impairment: a systematic review and meta-analysis. Aging Clin. Exp. Res. 36, 60 (2024).","journal-title":"Aging Clin. Exp. Res."},{"key":"1163_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49402-x","volume":"15","author":"SE Mastenbroek","year":"2024","unstructured":"Mastenbroek, S. E. et al. Disease progression modelling reveals heterogeneity in trajectories of Lewy-type \u03b1-synuclein pathology. Nat. Commun. 15, 5133 (2024).","journal-title":"Nat. Commun."},{"key":"1163_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41582-021-00486-9","volume":"17","author":"D Berg","year":"2021","unstructured":"Berg, D. et al. Prodromal Parkinson disease subtypes \u2014 key to understanding heterogeneity. Nat. Rev. Neurol. 17, 349\u2013361 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1163_CR32","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/brain\/awz111","volume":"142","author":"SM Fereshtehnejad","year":"2019","unstructured":"Fereshtehnejad, S. M. et al. Evolution of prodromal Parkinson\u2019s disease and dementia with Lewy bodies: a prospective study. Brain 142, 2051\u20132067 (2019).","journal-title":"Brain"},{"key":"1163_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70066","volume":"17","author":"EA Bernal","year":"2024","unstructured":"Bernal, E. A., Yang, S., Herbst, K. & Venuto, C. S. Comparing machine learning and deep learning models to predict cognition progression in Parkinson\u2019s disease. Clin. Transl. Sci. 17, e70066 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41531-023-00556-3","volume":"9","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Two distinct trajectories of clinical and neurodegeneration events in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 111 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12020199","volume":"12","author":"DHB Speelberg","year":"2022","unstructured":"Speelberg, D. H. B. et al. Prodromal cognitive deficits and the risk of subsequent Parkinson\u2019s disease. Brain Sci. 12, 199 (2022).","journal-title":"Brain Sci."},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.parkreldis.2019.04.020","volume":"65","author":"D Saredakis","year":"2019","unstructured":"Saredakis, D., Collins-Praino, L. E., Gutteridge, D. S., Stephan, B. C. M. & Keage, H. A. D. Conversion to MCI and dementia in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 65, 20\u201331 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00021","volume":"11","author":"A Nicoletti","year":"2019","unstructured":"Nicoletti, A. et al. Incidence of mild cognitive impairment and dementia in Parkinson\u2019s disease: the Parkinson\u2019s Disease Cognitive Impairment Study. Front. Aging Neurosci. 11, 21 (2019).","journal-title":"Front. Aging Neurosci."},{"key":"1163_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrneurol.2012.80","volume":"8","author":"RL Doty","year":"2012","unstructured":"Doty, R. L. Olfactory dysfunction in Parkinson disease. Nat. Rev. Neurol. 8, 329\u2013339 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"1163_CR39","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma, R. B. et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142, 744\u2013759 (2019).","journal-title":"Brain"},{"key":"1163_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41531-023-00598-7","volume":"9","author":"A Seger","year":"2023","unstructured":"Seger, A. et al. Clinical subtypes in patients with isolated REM sleep behaviour disorder. NPJ Parkinsons Dis. 9, 155 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf191","author":"G Chiaro","year":"2025","unstructured":"Chiaro, G. et al. Pure autonomic failure: a natural history study of the Queen Square cohort. Brain https:\/\/doi.org\/10.1093\/brain\/awaf191 (2025).","journal-title":"Brain"},{"key":"1163_CR42","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1093\/brain\/awad072","volume":"146","author":"S Joza","year":"2023","unstructured":"Joza, S. et al. Progression of clinical markers in prodromal Parkinson\u2019s disease and dementia with Lewy bodies: a multicentre study. Brain 146, 3258\u20133272 (2023).","journal-title":"Brain"},{"key":"1163_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/alz.13386","volume":"20","author":"S Joza","year":"2024","unstructured":"Joza, S. et al. Prodromal dementia with Lewy bodies in REM sleep behavior disorder: a multicenter study. Alzheimers Dement. 20, 91\u2013102 (2024).","journal-title":"Alzheimers Dement."},{"key":"1163_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333865","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Visuospatial dysfunction predicts dementia-first phenoconversion in isolated REM sleep behaviour disorder. J. Neurol. Neurosurg. Psychiatry https:\/\/doi.org\/10.1136\/jnnp-2024-333865 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1163_CR45","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1111\/ene.16001","volume":"30","author":"D Arnaldi","year":"2023","unstructured":"Arnaldi, D. et al. Clinical and dopaminergic imaging characteristics of the FARPRESTO cohort of trial-ready idiopathic rapid eye movement sleep behavior patients. Eur. J. Neurol. 30, 3703\u20133710 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1163_CR46","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ana.26902","volume":"95","author":"D Arnaldi","year":"2024","unstructured":"Arnaldi, D. et al. Presynaptic dopaminergic imaging characterizes patients with REM sleep behavior disorder due to synucleinopathy. Ann. Neurol. 95, 1178\u20131192 (2024).","journal-title":"Ann. Neurol."},{"key":"1163_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac071","volume":"45","author":"JK Hong","year":"2022","unstructured":"Hong, J. K. et al. Clinical manifestation of patients with isolated rapid eye movement sleep behavior disorder after modest-to-long disease duration. Sleep 45, zsac071 (2022).","journal-title":"Sleep"},{"key":"1163_CR48","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ana.26835","volume":"95","author":"M Subert","year":"2024","unstructured":"Subert, M. et al. Spoken language alterations can predict phenoconversion in isolated rapid eye movement sleep behavior disorder: a multicenter study. Ann. Neurol. 95, 530\u2013543 (2024).","journal-title":"Ann. Neurol."},{"key":"1163_CR49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3233\/JPD-212984","volume":"12","author":"S Zolfaghari","year":"2022","unstructured":"Zolfaghari, S. et al. Cardiovascular risk factors and phenoconversion to neurodegenerative synucleinopathies in idiopathic REM sleep behavior disorder. J. Parkinsons Dis. 12, 927\u2013933 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1163_CR50","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/brain\/awae033","volume":"147","author":"P Millar Vernetti","year":"2024","unstructured":"Millar Vernetti, P. et al. Phenoconversion in pure autonomic failure: a multicentre prospective longitudinal cohort study. Brain 147, 2440\u20132448 (2024).","journal-title":"Brain"},{"key":"1163_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"1163_CR52","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210279","volume":"104","author":"DG Coughlin","year":"2025","unstructured":"Coughlin, D. G. et al. \u03b1-Synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease. Neurology 104, e210279 (2025).","journal-title":"Neurology"},{"key":"1163_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01653-3","volume":"11","author":"S Brauer","year":"2023","unstructured":"Brauer, S. et al. Kinetic parameters of \u03b1-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders. Acta Neuropathol. Commun. 11, 162 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"1163_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00627-5","volume":"10","author":"K Brockmann","year":"2024","unstructured":"Brockmann, K. et al. CSF \u03b1-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson\u2019s disease. NPJ Parkinsons Dis. 10, 24 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR55","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1093\/brain\/awae405","volume":"148","author":"A Mastrangelo","year":"2025","unstructured":"Mastrangelo, A. et al. \u03b1-Synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum. Brain 148, 2038\u20132048 (2025).","journal-title":"Brain"},{"key":"1163_CR56","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/mdc3.13751","volume":"10","author":"D Weintraub","year":"2023","unstructured":"Weintraub, D. et al. Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study. Mov. Disord. Clin. Pract. 10, 943\u2013955 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1163_CR57","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.parkreldis.2018.02.048","volume":"51","author":"SJ Chung","year":"2018","unstructured":"Chung, S. J. et al. Effect of striatal dopamine depletion on cognition in de novo Parkinson\u2019s disease. Parkinsonism Relat. Disord. 51, 43\u201348 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR58","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1212\/WNL.0000000000009878","volume":"95","author":"SJ Chung","year":"2020","unstructured":"Chung, S. J. et al. Patterns of striatal dopamine depletion in early Parkinson disease: prognostic relevance. Neurology 95, e280\u2013e290 (2020).","journal-title":"Neurology"},{"key":"1163_CR59","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of Parkinson\u2019s disease. Lancet 403, 293\u2013304 (2024).","journal-title":"Lancet"},{"key":"1163_CR60","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.3390\/ijms26115405","volume":"26","author":"O Arias-Carrion","year":"2025","unstructured":"Arias-Carrion, O., Guerra-Crespo, M., Padilla-Godinez, F. J., Soto-Rojas, L. O. & Manjarrez, E. \u03b1-Synuclein pathology in synucleinopathies: mechanisms, biomarkers, and therapeutic challenges. Int. J. Mol. Sci. 26, 5405 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi, P. et al. \u03b1-Synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 14, 176 (2023).","journal-title":"Cell Death Dis."},{"key":"1163_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47227-z","volume":"9","author":"AJ Schaser","year":"2019","unstructured":"Schaser, A. J. et al. \u03b1-Synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders. Sci. Rep. 9, 10919 (2019).","journal-title":"Sci. Rep."},{"key":"1163_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bpa.12344","volume":"27","author":"JH Power","year":"2017","unstructured":"Power, J. H., Barnes, O. L. & Chegini, F. Lewy bodies and the mechanisms of neuronal cell death in Parkinson\u2019s disease and dementia with Lewy bodies. Brain Pathol. 27, 3\u201312 (2017).","journal-title":"Brain Pathol."},{"key":"1163_CR64","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/pnas.1913904117","volume":"117","author":"AL Mahul-Mellier","year":"2020","unstructured":"Mahul-Mellier, A. L. et al. The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl Acad. Sci. USA 117, 4971\u20134982 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR65","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/mds.29897","volume":"39","author":"J Burre","year":"2024","unstructured":"Burre, J. et al. Research priorities on the role of \u03b1-synuclein in Parkinson\u2019s disease pathogenesis. Mov. Disord. 39, 1663\u20131678 (2024).","journal-title":"Mov. Disord."},{"key":"1163_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00614-w","volume":"10","author":"JA Wiseman","year":"2024","unstructured":"Wiseman, J. A. et al. Aggregate-prone brain regions in Parkinson\u2019s disease are rich in unique N-terminus \u03b1-synuclein conformers with high proteolysis susceptibility. NPJ Parkinsons Dis. 10, 1 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR67","doi-asserted-by":"publisher","first-page":"8338","DOI":"10.3390\/ijms22158338","volume":"22","author":"A Jan","year":"2021","unstructured":"Jan, A., Goncalves, N. P., Vaegter, C. B., Jensen, P. H. & Ferreira, N. The prion-like spreading of \u03b1-synuclein in Parkinson\u2019s disease: update on models and hypotheses. Int. J. Mol. Sci. 22, 8338 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR68","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41583-024-00806-0","volume":"25","author":"M Kampmann","year":"2024","unstructured":"Kampmann, M. Molecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases. Nat. Rev. Neurosci. 25, 351\u2013371 (2024).","journal-title":"Nat. Rev. Neurosci."},{"key":"1163_CR69","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.neuron.2023.03.021","volume":"111","author":"M Carceles-Cordon","year":"2023","unstructured":"Carceles-Cordon, M., Weintraub, D. & Chen-Plotkin, A. S. Cognitive heterogeneity in Parkinson\u2019s disease: a mechanistic view. Neuron 111, 1531\u20131546 (2023).","journal-title":"Neuron"},{"key":"1163_CR70","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00401-019-02071-3","volume":"138","author":"A Raunio","year":"2019","unstructured":"Raunio, A. et al. Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85. Acta Neuropathol. 138, 771\u2013782 (2019).","journal-title":"Acta Neuropathol."},{"key":"1163_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00436-2","volume":"8","author":"P Borghammer","year":"2022","unstructured":"Borghammer, P. et al. A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 166 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR72","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00702-023-02633-6","volume":"130","author":"P Borghammer","year":"2023","unstructured":"Borghammer, P. The brain-first vs. body-first model of Parkinson\u2019s disease with comparison to alternative models. J. Neural Transm. 130, 737\u2013753 (2023).","journal-title":"J. Neural Transm."},{"key":"1163_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105753","volume":"117","author":"S Joza","year":"2025","unstructured":"Joza, S. et al. Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder. EBioMedicine 117, 105753 (2025).","journal-title":"EBioMedicine"},{"key":"1163_CR74","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 103, 627\u2013641.e7 (2019).","journal-title":"Neuron"},{"key":"1163_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01388-7","volume":"10","author":"S Hall","year":"2022","unstructured":"Hall, S. et al. Performance of \u03b1Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathol. Commun. 10, 90 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1163_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42705-5","volume":"14","author":"N Uemura","year":"2023","unstructured":"Uemura, N. et al. \u03b1-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice. Nat. Commun. 14, 6892 (2023).","journal-title":"Nat. Commun."},{"key":"1163_CR77","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.stemcr.2018.12.007","volume":"12","author":"S Gribaudo","year":"2019","unstructured":"Gribaudo, S. et al. Propagation of \u03b1-synuclein strains within human reconstructed neuronal network. Stem Cell Rep. 12, 230\u2013244 (2019).","journal-title":"Stem Cell Rep."},{"key":"1163_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168011","volume":"435","author":"RWL So","year":"2023","unstructured":"So, R. W. L. & Watts, J. C. \u03b1-Synuclein conformational strains as drivers of phenotypic heterogeneity in neurodegenerative diseases. J. Mol. Biol. 435, 168011 (2023).","journal-title":"J. Mol. Biol."},{"key":"1163_CR79","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","volume":"139","author":"A Van der Perren","year":"2020","unstructured":"Van der Perren, A. et al. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 139, 977\u20131000 (2020).","journal-title":"Acta Neuropathol."},{"key":"1163_CR80","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","volume":"610","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Structures of \u03b1-synuclein filaments from human brains with Lewy pathology. Nature 610, 791\u2013795 (2022).","journal-title":"Nature"},{"key":"1163_CR81","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/WNL.54.10.1916","volume":"54","author":"HI Hurtig","year":"2000","unstructured":"Hurtig, H. I. et al. \u03b1-synuclein cortical Lewy bodies correlate with dementia in Parkinson\u2019s disease. Neurology 54, 1916\u20131921 (2000).","journal-title":"Neurology"},{"key":"1163_CR82","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1212\/01.WNL.0000158422.41380.82","volume":"64","author":"H Braak","year":"2005","unstructured":"Braak, H., Rub, U., Jansen Steur, E. N., Del Tredici, K. & de Vos, R. A. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64, 1404\u20131410 (2005).","journal-title":"Neurology"},{"key":"1163_CR83","first-page":"1234","volume":"90","author":"C Smith","year":"2019","unstructured":"Smith, C. et al. Neuropathology of dementia in patients with Parkinson\u2019s disease: a systematic review of autopsy studies. J. Neurol. Neurosurg. Psychiatry 90, 1234\u20131243 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1163_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01711-w","volume":"12","author":"I Frigerio","year":"2024","unstructured":"Frigerio, I. et al. Regional differences in synaptic degeneration are linked to \u03b1-synuclein burden and axonal damage in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 12, 4 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"1163_CR85","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/mds.27991","volume":"35","author":"MG Knox","year":"2020","unstructured":"Knox, M. G. et al. Neuropathological findings in Parkinson\u2019s disease with mild cognitive impairment. Mov. Disord. 35, 845\u2013850 (2020).","journal-title":"Mov. Disord."},{"key":"1163_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010498","volume":"25","author":"KA Jellinger","year":"2023","unstructured":"Jellinger, K. A. Pathobiology of cognitive Impairment in Parkinson disease: challenges and outlooks. Int. J. Mol. Sci. 25, 498 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR87","doi-asserted-by":"publisher","first-page":"114651","DOI":"10.1016\/j.expneurol.2023.114651","volume":"372","author":"MF Manchinu","year":"2024","unstructured":"Manchinu, M. F. et al. Region-specific changes in gene expression are associated with cognitive deficits in the \u03b1-synuclein-induced model of Parkinson\u2019s disease: a transcriptomic profiling study. Exp. Neurol. 372, 114651 (2024).","journal-title":"Exp. Neurol."},{"key":"1163_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106072","volume":"122","author":"K Kawabata","year":"2024","unstructured":"Kawabata, K., Bagarinao, E., Seppi, K. & Poewe, W. Longitudinal brain changes in Parkinson\u2019s disease with severe olfactory deficit. Parkinsonism Relat. Disord. 122, 106072 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR89","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1212\/WNL.0000000000008822","volume":"94","author":"AJ Espay","year":"2020","unstructured":"Espay, A. J. et al. Author response: revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 94, 144\u2013145 (2020).","journal-title":"Neurology"},{"key":"1163_CR90","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/ana.26542","volume":"93","author":"WRW Martin","year":"2023","unstructured":"Martin, W. R. W. et al. Neocortical Lewy body pathology parallels Parkinson\u2019s dementia, but not always. Ann. Neurol. 93, 184\u2013195 (2023).","journal-title":"Ann. Neurol."},{"key":"1163_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.616357","volume":"12","author":"H Murakami","year":"2020","unstructured":"Murakami, H. et al. Mini review: correlations of cognitive domains with cerebrospinal fluid \u03b1-synuclein levels in patients with Parkinson\u2019s disease. Front. Aging Neurosci. 12, 616357 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"1163_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12708","volume":"48","author":"KA Jellinger","year":"2022","unstructured":"Jellinger, K. A. Morphological differences between dementia with Lewy bodies and Parkinson\u2019s disease-dementia. Neuropathol. Appl. Neurobiol. 48, e12708 (2022).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1163_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00391","volume":"10","author":"TR Melzer","year":"2019","unstructured":"Melzer, T. R. et al. Beta amyloid deposition is not associated with cognitive impairment in Parkinson\u2019s disease. Front. Neurol. 10, 391 (2019).","journal-title":"Front. Neurol."},{"key":"1163_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-022-00964-1","volume":"15","author":"AS Mihaescu","year":"2022","unstructured":"Mihaescu, A. S. et al. Beta amyloid deposition and cognitive decline in Parkinson\u2019s disease: a study of the PPMI cohort. Mol. Brain 15, 79 (2022).","journal-title":"Mol. Brain"},{"key":"1163_CR95","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1212\/WNL.0000000000200344","volume":"99","author":"PS Myers","year":"2022","unstructured":"Myers, P. S. et al. Proteinopathy and longitudinal cognitive decline in Parkinson disease. Neurology 99, e66\u2013e76 (2022).","journal-title":"Neurology"},{"key":"1163_CR96","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/acn3.51482","volume":"9","author":"RL Miller","year":"2022","unstructured":"Miller, R. L. et al. Quantifying regional \u03b1-synuclein, amyloid \u03b2, and tau accumulation in lewy body dementia. Ann. Clin. Transl. Neurol. 9, 106\u2013121 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1163_CR97","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","volume":"73","author":"SN Gomperts","year":"2016","unstructured":"Gomperts, S. N. et al. Tau positron emission tomographic imaging in the lewy body diseases. JAMA Neurol. 73, 1334\u20131341 (2016).","journal-title":"JAMA Neurol."},{"key":"1163_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00708-z","volume":"10","author":"M Matarazzo","year":"2024","unstructured":"Matarazzo, M. et al. Misfolded protein deposits in Parkinson\u2019s disease and Parkinson\u2019s disease-related cognitive impairment, a [11C]PBB3 study. NPJ Parkinsons Dis. 10, 96 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01913-w","volume":"13","author":"DL Fischer","year":"2025","unstructured":"Fischer, D. L. et al. Distinct subcellular localization of tau and \u03b1-synuclein in lewy body disease. Acta Neuropathol. Commun. 13, 14 (2025).","journal-title":"Acta Neuropathol. Commun."},{"key":"1163_CR100","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q. & LaFerla, F. M. Synergistic interactions between A\u03b2, tau, and \u03b1-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci. 30, 7281\u20137289 (2010).","journal-title":"J. Neurosci."},{"key":"1163_CR101","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192193","volume":"218","author":"F Bassil","year":"2021","unstructured":"Bassil, F. et al. \u03b1-Synuclein modulates tau spreading in mouse brains. J. Exp. Med. 218, e20192193 (2021).","journal-title":"J. Exp. Med."},{"key":"1163_CR102","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/mds.28342","volume":"36","author":"MMX Tan","year":"2021","unstructured":"Tan, M. M. X. et al. Genome-wide association studies of cognitive and motor progression in Parkinson\u2019s disease. Mov. Disord. 36, 424\u2013433 (2021).","journal-title":"Mov. Disord."},{"key":"1163_CR103","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/mds.28932","volume":"37","author":"AA Szwedo","year":"2022","unstructured":"Szwedo, A. A. et al. GBA and APOE impact cognitive decline in Parkinson\u2019s disease: a 10-year population-based study. Mov. Disord. 37, 1016\u20131027 (2022).","journal-title":"Mov. Disord."},{"key":"1163_CR104","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/brain\/awab402","volume":"145","author":"K Kaivola","year":"2022","unstructured":"Kaivola, K., Shah, Z., Chia, R., International LBD Genomics Consortium & Scholz, S. W. Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain 145, 1757\u20131762 (2022).","journal-title":"Brain"},{"key":"1163_CR105","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JAD-210365","volume":"83","author":"SJ van der Lee","year":"2021","unstructured":"van der Lee, S. J. et al. Genetics contributes to concomitant pathology and clinical presentation in dementia with lewy bodies. J. Alzheimers Dis. 83, 269\u2013279 (2021).","journal-title":"J. Alzheimers Dis."},{"key":"1163_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith, L. & Schapira, A. H. V. GBA variants and Parkinson disease: mechanisms and treatments. Cells 11, 1261 (2022).","journal-title":"Cells"},{"key":"1163_CR107","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1809","volume":"12","author":"N Zhao","year":"2020","unstructured":"Zhao, N. et al. APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid. Sci. Transl. Med. 12, eaay1809 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1163_CR108","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2011.07.047","volume":"310","author":"JH Somme","year":"2011","unstructured":"Somme, J. H. et al. Initial neuropsychological impairments in patients with the E46K mutation of the \u03b1-synuclein gene (PARK 1). J. Neurol. Sci. 310, 86\u201389 (2011).","journal-title":"J. Neurol. Sci."},{"key":"1163_CR109","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JPD-150762","volume":"6","author":"KC Paul","year":"2016","unstructured":"Paul, K. C. et al. APOE, MAPT, and COMT and Parkinson\u2019s disease susceptibility and cognitive symptom progression. J. Parkinsons Dis. 6, 349\u2013359 (2016).","journal-title":"J. Parkinsons Dis."},{"key":"1163_CR110","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neulet.2013.12.051","volume":"561","author":"M Bialecka","year":"2014","unstructured":"Bialecka, M. et al. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson\u2019s disease. Neurosci. Lett. 561, 86\u201390 (2014).","journal-title":"Neurosci. Lett."},{"key":"1163_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175674","volume":"12","author":"C Caspell-Garcia","year":"2017","unstructured":"Caspell-Garcia, C. et al. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLoS ONE 12, e0175674 (2017).","journal-title":"PLoS ONE"},{"key":"1163_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00619-5","volume":"10","author":"J Faouzi","year":"2024","unstructured":"Faouzi, J. et al. Proxy-analysis of the genetics of cognitive decline in Parkinson\u2019s disease through polygenic scores. NPJ Parkinsons Dis. 10, 8 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR113","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","volume":"53","author":"R Chia","year":"2021","unstructured":"Chia, R. et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat. Genet. 53, 294\u2013303 (2021).","journal-title":"Nat. Genet."},{"key":"1163_CR114","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.cell.2018.01.008","volume":"172","author":"C Liu","year":"2018","unstructured":"Liu, C., Kershberg, L., Wang, J., Schneeberger, S. & Kaeser, P. S. Dopamine secretion is mediated by sparse active zone-like release sites. Cell 172, 706\u2013718.e5 (2018).","journal-title":"Cell"},{"key":"1163_CR115","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1073\/pnas.1618213114","volume":"114","author":"HF Jiao","year":"2017","unstructured":"Jiao, H. F. et al. Transmembrane protein 108 is required for glutamatergic transmission in dentate gyrus. Proc. Natl Acad. Sci. USA 114, 1177\u20131182 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR116","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41588-021-00847-6","volume":"53","author":"G Liu","year":"2021","unstructured":"Liu, G. et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson\u2019s disease. Nat. Genet. 53, 787\u2013793 (2021).","journal-title":"Nat. Genet."},{"key":"1163_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106887","volume":"208","author":"YT Yuan","year":"2025","unstructured":"Yuan, Y. T., Hong, W. P., Tan, C. H. & Yu, R. L. Influence of WWOX\/MAF genes on cognitive performance in patients with Parkinson\u2019s disease. Neurobiol. Dis. 208, 106887 (2025).","journal-title":"Neurobiol. Dis."},{"key":"1163_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/biom13050802","volume":"13","author":"T Tang","year":"2023","unstructured":"Tang, T., Jian, B. & Liu, Z. Transmembrane protein 175, a lysosomal Ion channel related to Parkinson\u2019s disease. Biomolecules 13, 802 (2023).","journal-title":"Biomolecules"},{"key":"1163_CR119","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1073\/pnas.1616332114","volume":"114","author":"S Jinn","year":"2017","unstructured":"Jinn, S. et al. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases \u03b1-synuclein aggregation. Proc. Natl Acad. Sci. USA 114, 2389\u20132394 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR120","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.cell.2022.05.021","volume":"185","author":"M Hu","year":"2022","unstructured":"Hu, M. et al. Parkinson\u2019s disease-risk protein TMEM175 is a proton-activated proton channel in lysosomes. Cell 185, 2292\u20132308.e20 (2022).","journal-title":"Cell"},{"key":"1163_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37815-z","volume":"14","author":"T Fujii","year":"2023","unstructured":"Fujii, T. et al. Parkinson\u2019s disease-associated ATP13A2\/PARK9 functions as a lysosomal H+,K+-ATPase. Nat. Commun. 14, 2174 (2023).","journal-title":"Nat. Commun."},{"key":"1163_CR122","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/mds.29698","volume":"39","author":"JA Tunold","year":"2024","unstructured":"Tunold, J. A. et al. Lysosomal polygenic burden drives cognitive decline in Parkinson\u2019s disease with low alzheimer risk. Mov. Disord. 39, 596\u2013601 (2024).","journal-title":"Mov. Disord."},{"key":"1163_CR123","doi-asserted-by":"publisher","DOI":"10.1126\/science.abk0637","volume":"377","author":"ME Diaz-Ortiz","year":"2022","unstructured":"Diaz-Ortiz, M. E. et al. GPNMB confers risk for Parkinson\u2019s disease through interaction with \u03b1-synuclein. Science 377, eabk0637 (2022).","journal-title":"Science"},{"key":"1163_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228421","volume":"21","author":"C Marogianni","year":"2020","unstructured":"Marogianni, C. et al. Neurodegeneration and inflammation \u2014 an interesting interplay in Parkinson\u2019s disease. Int. J. Mol. Sci. 21, 8421 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/cells11182908","volume":"11","author":"B Araujo","year":"2022","unstructured":"Araujo, B. et al. Neuroinflammation and Parkinson\u2019s disease \u2014 from neurodegeneration to therapeutic opportunities. Cells 11, 2908 (2022).","journal-title":"Cells"},{"key":"1163_CR126","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3233\/JPD-240353","volume":"14","author":"B Patel","year":"2024","unstructured":"Patel, B., Greenland, J. C. & Williams-Gray, C. H. Clinical trial highlights: anti-inflammatory and immunomodulatory agents. J. Parkinsons Dis. 14, 1283\u20131300 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1163_CR127","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrneurol.2013.275","volume":"10","author":"HJ Lee","year":"2014","unstructured":"Lee, H. J., Bae, E. J. & Lee, S. J. Extracellular \u03b1-synuclein \u2014 a novel and crucial factor in lewy body diseases. Nat. Rev. Neurol. 10, 92\u201398 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"1163_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126517","volume":"22","author":"A Cardinale","year":"2021","unstructured":"Cardinale, A., Calabrese, V., de Iure, A. & Picconi, B. \u03b1-Synuclein as a prominent actor in the inflammatory synaptopathy of Parkinson\u2019s disease. Int. J. Mol. Sci. 22, 6517 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR129","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00441-017-2775-9","volume":"373","author":"V Grozdanov","year":"2018","unstructured":"Grozdanov, V. & Danzer, K. M. Release and uptake of pathologic \u03b1-synuclein. Cell Tissue Res. 373, 175\u2013182 (2018).","journal-title":"Cell Tissue Res."},{"key":"1163_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-015-0198-y","volume":"3","author":"A Ulusoy","year":"2015","unstructured":"Ulusoy, A. et al. Neuron-to-neuron \u03b1-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathol. Commun. 3, 13 (2015).","journal-title":"Acta Neuropathol. Commun."},{"key":"1163_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim, C. et al. Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).","journal-title":"Nat. Commun."},{"key":"1163_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02496-w","volume":"19","author":"A Heidari","year":"2022","unstructured":"Heidari, A., Yazdanpanah, N. & Rezaei, N. The role of Toll-like receptors and neuroinflammation in Parkinson\u2019s disease. J. Neuroinflammation 19, 135 (2022).","journal-title":"J. Neuroinflammation"},{"key":"1163_CR133","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4049\/jimmunol.2100035","volume":"207","author":"H Scheiblich","year":"2021","unstructured":"Scheiblich, H. et al. Microglial NLRP3 inflammasome activation upon TLR2 and TLR5 Ligation by distinct \u03b1-synuclein assemblies. J. Immunol. 207, 2143\u20132154 (2021).","journal-title":"J. Immunol."},{"key":"1163_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094676","volume":"22","author":"K Badanjak","year":"2021","unstructured":"Badanjak, K., Fixemer, S., Smajic, S., Skupin, A. & Grunewald, A. The contribution of microglia to neuroinflammation in Parkinson\u2019s disease. Int. J. Mol. Sci. 22, 4676 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR135","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mds.28264","volume":"36","author":"AS Harms","year":"2021","unstructured":"Harms, A. S. et al. Inflammation in experimental models of \u03b1-synucleinopathies. Mov. Disord. 36, 37\u201349 (2021).","journal-title":"Mov. Disord."},{"key":"1163_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01083-5","volume":"8","author":"A Kouli","year":"2020","unstructured":"Kouli, A., Camacho, M., Allinson, K. & Williams-Gray, C. H. Neuroinflammation and protein pathology in Parkinson\u2019s disease dementia. Acta Neuropathol. Commun. 8, 211 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1163_CR137","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","volume":"33","author":"D Lindqvist","year":"2013","unstructured":"Lindqvist, D. et al. Cerebrospinal fluid inflammatory markers in Parkinson\u2019s disease-associations with depression, fatigue, and cognitive impairment. Brain Behav. Immun. 33, 183\u2013189 (2013).","journal-title":"Brain Behav. Immun."},{"key":"1163_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31517-z","volume":"8","author":"S Hall","year":"2018","unstructured":"Hall, S. et al. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson\u2019s disease and atypical parkinsonian disorders. Sci. Rep. 8, 13276 (2018).","journal-title":"Sci. Rep."},{"key":"1163_CR139","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.26563","volume":"31","author":"CH Williams-Gray","year":"2016","unstructured":"Williams-Gray, C. H. et al. Serum immune markers and disease progression in an incident Parkinson\u2019s disease cohort (ICICLE-PD). Mov. Disord. 31, 995\u20131003 (2016).","journal-title":"Mov. Disord."},{"key":"1163_CR140","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/JPD-223277","volume":"12","author":"M Zimmermann","year":"2022","unstructured":"Zimmermann, M. & Brockmann, K. Blood and cerebrospinal fluid biomarkers of inflammation in Parkinson\u2019s disease. J. Parkinsons Dis. 12, S183\u2013S200 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1163_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578484","volume":"398","author":"Z Jiang","year":"2025","unstructured":"Jiang, Z. et al. The role of the immune system in Parkinson\u2019s disease pathogenesis: a focus on Th17 cells \u2014 a systematic review and meta-analysis. J. Neuroimmunol. 398, 578484 (2025).","journal-title":"J. Neuroimmunol."},{"key":"1163_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-113","volume":"14","author":"SY Yu","year":"2014","unstructured":"Yu, S. Y. et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol. 14, 113 (2014).","journal-title":"BMC Neurol."},{"key":"1163_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.875059","volume":"14","author":"DN Li","year":"2022","unstructured":"Li, D. N. et al. Potential roles of oxidative distress on neurodegeneration in Parkinson\u2019s disease with neuropsychiatric symptoms. Front. Aging Neurosci. 14, 875059 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1163_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/antiox8080265","volume":"8","author":"A Rizor","year":"2019","unstructured":"Rizor, A., Pajarillo, E., Johnson, J., Aschner, M. & Lee, E. Astrocytic Oxidative\/Nitrosative stress contributes to Parkinson\u2019s disease pathogenesis: the dual role of reactive astrocytes. Antioxidants 8, 265 (2019).","journal-title":"Antioxidants"},{"key":"1163_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00447-7","volume":"9","author":"Y Tang","year":"2023","unstructured":"Tang, Y. et al. Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia. NPJ Parkinsons Dis. 9, 23 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02843-5","volume":"20","author":"T Liu","year":"2023","unstructured":"Liu, T. et al. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer\u2019s disease-associated biomarkers alterations among de novo Parkinson\u2019s disease patients: a prospective cohort study. J. Neuroinflammation 20, 167 (2023).","journal-title":"J. Neuroinflammation"},{"key":"1163_CR147","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/mds.29363","volume":"38","author":"TA Yacoubian","year":"2023","unstructured":"Yacoubian, T. A. et al. Brain and systemic inflammation in de novo Parkinson\u2019s disease. Mov. Disord. 38, 743\u2013754 (2023).","journal-title":"Mov. Disord."},{"key":"1163_CR148","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1317-z","volume":"15","author":"PL Chiang","year":"2018","unstructured":"Chiang, P. L. et al. Interaction of systemic oxidative stress and mesial temporal network degeneration in Parkinson\u2019s disease with and without cognitive impairment. J. Neuroinflammation 15, 281 (2018).","journal-title":"J. Neuroinflammation"},{"key":"1163_CR149","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ana.26410","volume":"92","author":"J Shen","year":"2022","unstructured":"Shen, J. et al. Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson\u2019s disease. Ann. Neurol. 92, 255\u2013269 (2022).","journal-title":"Ann. Neurol."},{"key":"1163_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.548283","volume":"8","author":"YM Jeon","year":"2020","unstructured":"Jeon, Y. M. et al. The role of glial mitochondria in \u03b1-synuclein toxicity. Front. Cell Dev. Biol. 8, 548283 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1163_CR151","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/mds.26513","volume":"31","author":"AP Gatt","year":"2016","unstructured":"Gatt, A. P. et al. Dementia in Parkinson\u2019s disease is associated with enhanced mitochondrial complex I deficiency. Mov. Disord. 31, 352\u2013359 (2016).","journal-title":"Mov. Disord."},{"key":"1163_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47867-4","volume":"15","author":"IH Flones","year":"2024","unstructured":"Flones, I. H. et al. Mitochondrial complex I deficiency stratifies idiopathic Parkinson\u2019s disease. Nat. Commun. 15, 3631 (2024).","journal-title":"Nat. Commun."},{"key":"1163_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111490","volume":"25","author":"A Scorziello","year":"2024","unstructured":"Scorziello, A. et al. Mitochondrial dysfunction in Parkinson\u2019s disease: a contribution to cognitive impairment? Int. J. Mol. Sci. 25, 11490 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11112141","volume":"11","author":"DF Silva","year":"2022","unstructured":"Silva, D. F., Empadinhas, N., Cardoso, S. M. & Esteves, A. R. Neurodegenerative microbially-shaped diseases: oxidative stress meets neuroinflammation. Antioxidants 11, 2141 (2022).","journal-title":"Antioxidants"},{"key":"1163_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103092","volume":"71","author":"B Kalyanaraman","year":"2024","unstructured":"Kalyanaraman, B., Cheng, G. & Hardy, M. Gut microbiome, short-chain fatty acids, \u03b1-synuclein, neuroinflammation, and ROS\/RNS: relevance to Parkinson\u2019s disease and therapeutic implications. Redox Biol. 71, 103092 (2024).","journal-title":"Redox Biol."},{"key":"1163_CR156","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1007\/s12035-021-02375-0","volume":"58","author":"Y Liang","year":"2021","unstructured":"Liang, Y. et al. Gut microbial metabolites in Parkinson\u2019s disease: implications of mitochondrial dysfunction in the pathogenesis and treatment. Mol. Neurobiol. 58, 3745\u20133758 (2021).","journal-title":"Mol. Neurobiol."},{"key":"1163_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.945523","volume":"13","author":"D Li","year":"2022","unstructured":"Li, D., Ren, T., Li, H., Liao, G. & Zhang, X. Porphyromonas gingivalis: a key role in Parkinson\u2019s disease with cognitive impairment? Front. Neurol. 13, 945523 (2022).","journal-title":"Front. Neurol."},{"key":"1163_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1298546","volume":"14","author":"O Laugisch","year":"2024","unstructured":"Laugisch, O. et al. Glucose-6-phosphatase-dehydrogenase activity as modulative association between Parkinson\u2019s disease and periodontitis. Front. Cell Infect. Microbiol. 14, 1298546 (2024).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1163_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144130","volume":"13","author":"E Caradonna","year":"2024","unstructured":"Caradonna, E. et al. The brain-gut axis, an important player in Alzheimer and Parkinson disease: a narrative review. J. Clin. Med. 13, 4130 (2024).","journal-title":"J. Clin. Med."},{"key":"1163_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02782-1","volume":"20","author":"J Yu","year":"2023","unstructured":"Yu, J. et al. Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease. J. Neuroinflammation 20, 117 (2023).","journal-title":"J. Neuroinflammation"},{"key":"1163_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/biom12050655","volume":"12","author":"C Chavarria","year":"2022","unstructured":"Chavarria, C., Ivagnes, R. & Souza, J. M. Extracellular \u03b1-synuclein: mechanisms for glial cell internalization and activation. Biomolecules 12, 655 (2022).","journal-title":"Biomolecules"},{"key":"1163_CR162","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s12264-021-00651-6","volume":"37","author":"N Song","year":"2021","unstructured":"Song, N., Chen, L. & Xie, J. \u03b1-Synuclein handling by microglia: activating, combating, and worsening. Neurosci. Bull. 37, 751\u2013753 (2021).","journal-title":"Neurosci. Bull."},{"key":"1163_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03043-5","volume":"21","author":"C Yildirim-Balatan","year":"2024","unstructured":"Yildirim-Balatan, C. et al. Parkinson\u2019s disease-derived \u03b1-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype. J. Neuroinflammation 21, 54 (2024).","journal-title":"J. Neuroinflammation"},{"key":"1163_CR164","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","volume":"21","author":"NI Bohnen","year":"2022","unstructured":"Bohnen, N. I. et al. Cholinergic system changes in Parkinson\u2019s disease: emerging therapeutic approaches. Lancet Neurol. 21, 381\u2013392 (2022).","journal-title":"Lancet Neurol."},{"key":"1163_CR165","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1093\/brain\/awy072","volume":"141","author":"J Schulz","year":"2018","unstructured":"Schulz, J., Pagano, G., Fernandez Bonfante, J. A., Wilson, H. & Politis, M. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson\u2019s disease. Brain 141, 1501\u20131516 (2018).","journal-title":"Brain"},{"key":"1163_CR166","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/mds.30023","volume":"39","author":"NM Slater","year":"2024","unstructured":"Slater, N. M., Melzer, T. R., Myall, D. J., Anderson, T. J. & Dalrymple-Alford, J. C. Cholinergic basal forebrain integrity and cognition in Parkinson\u2019s disease: a reappraisal of magnetic resonance imaging evidence. Mov. Disord. 39, 2155\u20132172 (2024).","journal-title":"Mov. Disord."},{"key":"1163_CR167","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01678-x","volume":"17","author":"J Schumacher","year":"2025","unstructured":"Schumacher, J., Teipel, S. & Storch, A. Association of Alzheimer\u2019s and Lewy body disease pathology with basal forebrain volume and cognitive impairment. Alzheimers Res. Ther. 17, 28 (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"1163_CR168","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.parkreldis.2021.05.027","volume":"88","author":"MJ Grothe","year":"2021","unstructured":"Grothe, M. J. et al. In vivo cholinergic basal forebrain degeneration and cognition in Parkinson\u2019s disease: imaging results from the COPPADIS study. Parkinsonism Relat. Disord. 88, 68\u201375 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR169","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/brain\/awx310","volume":"141","author":"NJ Ray","year":"2018","unstructured":"Ray, N. J. et al. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson\u2019s disease. Brain 141, 165\u2013176 (2018).","journal-title":"Brain"},{"key":"1163_CR170","doi-asserted-by":"publisher","first-page":"e1301","DOI":"10.1212\/WNL.0000000000010192","volume":"95","author":"SJ Teipel","year":"2020","unstructured":"Teipel, S. J., Fritz, H. C. & Grothe, M. J.Alzheimer\u2019s Disease Neuroimaging Initiative Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. Neurology 95, e1301\u2013e1311 (2020).","journal-title":"Neurology"},{"key":"1163_CR171","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/mds.29564","volume":"38","author":"MA Labrador-Espinosa","year":"2023","unstructured":"Labrador-Espinosa, M. A., Silva-Rodriguez, J., Reina-Castillo, M. I., Mir, P. & Grothe, M. J. Basal Forebrain atrophy, cortical thinning, and amyloid-\u03b2 status in Parkinson\u2019s disease-related cognitive decline. Mov. Disord. 38, 1871\u20131880 (2023).","journal-title":"Mov. Disord."},{"key":"1163_CR172","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00401-015-1392-5","volume":"129","author":"AK Liu","year":"2015","unstructured":"Liu, A. K., Chang, R. C., Pearce, R. K. & Gentleman, S. M. Nucleus basalis of meynert revisited: anatomy, history and differential involvement in Alzheimer\u2019s and Parkinson\u2019s disease. Acta Neuropathol. 129, 527\u2013540 (2015).","journal-title":"Acta Neuropathol."},{"key":"1163_CR173","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nan.12298","volume":"42","author":"K Del Tredici","year":"2016","unstructured":"Del Tredici, K. & Braak, H. Review: Sporadic Parkinson\u2019s disease: development and distribution of \u03b1-synuclein pathology. Neuropathol. Appl. Neurobiol. 42, 33\u201350 (2016).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1163_CR174","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaneurol.2024.2713","volume":"81","author":"LEM Wisse","year":"2024","unstructured":"Wisse, L. E. M. et al. MRI signature of \u03b1-synuclein pathology in asymptomatic stages and a memory clinic population. JAMA Neurol. 81, 1051\u20131059 (2024).","journal-title":"JAMA Neurol."},{"key":"1163_CR175","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/brain\/awab372","volume":"145","author":"J Schumacher","year":"2022","unstructured":"Schumacher, J. et al. Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer\u2019s disease. Brain 145, 1773\u20131784 (2022).","journal-title":"Brain"},{"key":"1163_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106243","volume":"185","author":"RA Crockett","year":"2023","unstructured":"Crockett, R. A., Wilkins, K. B., Aditham, S. & Bronte-Stewart, H. M. No laughing white matter: reduced integrity of the cortical cholinergic pathways in Parkinson\u2019s disease-related cognitive impairment. Neurobiol. Dis. 185, 106243 (2023).","journal-title":"Neurobiol. Dis."},{"key":"1163_CR177","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1093\/brain\/awad192","volume":"146","author":"N Okkels","year":"2023","unstructured":"Okkels, N. et al. Severe cholinergic terminal loss in newly diagnosed dementia with Lewy bodies. Brain 146, 3690\u20133704 (2023).","journal-title":"Brain"},{"key":"1163_CR178","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/jnnp.48.5.413","volume":"48","author":"EK Perry","year":"1985","unstructured":"Perry, E. K. et al. Cholinergic correlates of cognitive impairment in Parkinson\u2019s disease: comparisons with Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 48, 413\u2013421 (1985).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1163_CR179","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s007020050176","volume":"106","author":"CF Lippa","year":"1999","unstructured":"Lippa, C. F., Smith, T. W. & Perry, E. Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J. Neural Transm. 106, 525\u2013535 (1999).","journal-title":"J. Neural Transm."},{"key":"1163_CR180","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/brain\/aww098","volume":"139","author":"AK Hansen","year":"2016","unstructured":"Hansen, A. K. et al. In vivo imaging of neuromelanin in Parkinson\u2019s disease using 18F-AV-1451 PET. Brain 139, 2039\u20132049 (2016).","journal-title":"Brain"},{"key":"1163_CR181","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1093\/brain\/awab236","volume":"144","author":"CEJ Doppler","year":"2021","unstructured":"Doppler, C. E. J. et al. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson\u2019s disease. Brain 144, 2732\u20132744 (2021).","journal-title":"Brain"},{"key":"1163_CR182","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/brain\/awm302","volume":"131","author":"S Orimo","year":"2008","unstructured":"Orimo, S. et al. Axonal \u03b1-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson\u2019s disease. Brain 131, 642\u2013650 (2008).","journal-title":"Brain"},{"key":"1163_CR183","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq1141","volume":"9","author":"Q Wang","year":"2023","unstructured":"Wang, Q., Zheng, J., Pettersson, S., Reynolds, R. & Tan, E. K. The link between neuroinflammation and the neurovascular unit in synucleinopathies. Sci. Adv. 9, eabq1141 (2023).","journal-title":"Sci. Adv."},{"key":"1163_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80889-8","volume":"11","author":"O Elabi","year":"2021","unstructured":"Elabi, O. et al. Human \u03b1-synuclein overexpression in a mouse model of Parkinson\u2019s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation. Sci. Rep. 11, 1120 (2021).","journal-title":"Sci. Rep."},{"key":"1163_CR185","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ijbiomac.2022.12.134","volume":"229","author":"H Hourfar","year":"2023","unstructured":"Hourfar, H. et al. The impact of \u03b1-synuclein aggregates on blood-brain barrier integrity in the presence of neurovascular unit cells. Int. J. Biol. Macromol. 229, 305\u2013320 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"1163_CR186","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/brain\/awad226","volume":"146","author":"J Schumacher","year":"2023","unstructured":"Schumacher, J. et al. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson\u2019s disease. Brain 146, 4964\u20134973 (2023).","journal-title":"Brain"},{"key":"1163_CR187","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.parkreldis.2021.09.018","volume":"91","author":"C Legault-Denis","year":"2021","unstructured":"Legault-Denis, C. et al. Normal cognition in Parkinson\u2019s disease may involve hippocampal cholinergic compensation: an exploratory PET imaging study with [18F]-FEOBV. Parkinsonism Relat. Disord. 91, 162\u2013166 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00743-w","volume":"10","author":"J Schumacher","year":"2024","unstructured":"Schumacher, J., Ray, N., Teipel, S. & Storch, A. Associations of cholinergic system integrity with cognitive decline in GBA1 and LRRK2 mutation carriers. NPJ Parkinsons Dis. 10, 127 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR189","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14584","volume":"21","author":"KA Woo","year":"2025","unstructured":"Woo, K. A. et al. Cholinergic degeneration and early cognitive signs in prodromal lewy body dementia. Alzheimers Dement. 21, e14584 (2025).","journal-title":"Alzheimers Dement."},{"key":"1163_CR190","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3233\/JPD-223489","volume":"12","author":"J Horsager","year":"2022","unstructured":"Horsager, J. et al. Mapping cholinergic synaptic loss in Parkinson\u2019s disease: an [18F]FEOBV PET case-control study. J. Parkinsons Dis. 12, 2493\u20132506 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1163_CR191","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/mds.28913","volume":"37","author":"S van der Zee","year":"2022","unstructured":"van der Zee, S. et al. Altered cholinergic innervation in de novo Parkinson\u2019s disease with and without cognitive impairment. Mov. Disord. 37, 713\u2013723 (2022).","journal-title":"Mov. Disord."},{"key":"1163_CR192","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrn1886","volume":"7","author":"MP Mattson","year":"2006","unstructured":"Mattson, M. P. & Magnus, T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7, 278\u2013294 (2006).","journal-title":"Nat. Rev. Neurosci."},{"key":"1163_CR193","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ana.26596","volume":"93","author":"NJ Ray","year":"2023","unstructured":"Ray, N. J., Kanel, P. & Bohnen, N. I. Atrophy of the cholinergic basal forebrain can detect presynaptic cholinergic loss in Parkinson\u2019s disease. Ann. Neurol. 93, 991\u2013998 (2023).","journal-title":"Ann. Neurol."},{"key":"1163_CR194","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac320","volume":"4","author":"NI Bohnen","year":"2022","unstructured":"Bohnen, N. I. et al. Progression of regional cortical cholinergic denervation in Parkinson\u2019s disease. Brain Commun. 4, fcac320 (2022).","journal-title":"Brain Commun."},{"key":"1163_CR195","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/brain\/awac127","volume":"146","author":"NJ Ray","year":"2023","unstructured":"Ray, N. J. et al. Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson\u2019s disease. Brain 146, 1053\u20131064 (2023).","journal-title":"Brain"},{"key":"1163_CR196","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00429-019-02017-1","volume":"225","author":"M Febo","year":"2020","unstructured":"Febo, M. et al. Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-\u03b3. Brain Struct. Funct. 225, 427\u2013439 (2020).","journal-title":"Brain Struct. Funct."},{"key":"1163_CR197","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.1523\/JNEUROSCI.0189-20.2020","volume":"40","author":"WT Chu","year":"2020","unstructured":"Chu, W. T. et al. \u03b1-Synuclein induces progressive changes in brain microstructure and sensory-evoked brain function that precedes locomotor decline. J. Neurosci. 40, 6649\u20136659 (2020).","journal-title":"J. Neurosci."},{"key":"1163_CR198","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/brain\/awad420","volume":"147","author":"SJ Crowley","year":"2024","unstructured":"Crowley, S. J., Kanel, P., Roytman, S., Bohnen, N. I. & Hampstead, B. M. Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson\u2019s disease. Brain 147, 1799\u20131808 (2024).","journal-title":"Brain"},{"key":"1163_CR199","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaneurol.2014.2757","volume":"72","author":"NI Bohnen","year":"2015","unstructured":"Bohnen, N. I. et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol. 72, 194\u2013200 (2015).","journal-title":"JAMA Neurol."},{"key":"1163_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1006567","volume":"14","author":"S van der Zee","year":"2022","unstructured":"van der Zee, S., Kanel, P., Muller, M., van Laar, T. & Bohnen, N. I. Identification of cholinergic centro-cingulate topography as main contributor to cognitive functioning in Parkinson\u2019s disease: results from a data-driven approach. Front. Aging Neurosci. 14, 1006567 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1163_CR201","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/acn3.52257","volume":"12","author":"S Kang","year":"2025","unstructured":"Kang, S. et al. White matter hyperintensities and cholinergic degeneration as Lewy body disease. Ann. Clin. Transl. Neurol. 12, 97\u2013109 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1163_CR202","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neuroscience.2019.09.036","volume":"422","author":"Y Zhan","year":"2019","unstructured":"Zhan, Y., Raza, M. U., Yuan, L. & Zhu, M. Y. Critical role of oxidatively damaged DNA in selective noradrenergic vulnerability. Neuroscience 422, 184\u2013201 (2019).","journal-title":"Neuroscience"},{"key":"1163_CR203","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/mds.27682","volume":"34","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Mild cognitive impairment in de novo Parkinson\u2019s disease: a neuromelanin MRI study in locus coeruleus. Mov. Disord. 34, 884\u2013892 (2019).","journal-title":"Mov. Disord."},{"key":"1163_CR204","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/mds.30058","volume":"40","author":"Z Zeleznikova","year":"2025","unstructured":"Zeleznikova, Z. et al. Early changes in the locus coeruleus in mild cognitive impairment with lewy bodies. Mov. Disord. 40, 276\u2013284 (2025).","journal-title":"Mov. Disord."},{"key":"1163_CR205","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/bs.pbr.2022.01.013","volume":"269","author":"I Frouni","year":"2022","unstructured":"Frouni, I., Kwan, C., Belliveau, S. & Huot, P. Cognition and serotonin in Parkinson\u2019s disease. Prog. Brain Res. 269, 373\u2013403 (2022).","journal-title":"Prog. Brain Res."},{"key":"1163_CR206","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/mds.26236","volume":"30","author":"E Mamikonyan","year":"2015","unstructured":"Mamikonyan, E., Xie, S. X., Melvin, E. & Weintraub, D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov. Disord. 30, 912\u2013918 (2015).","journal-title":"Mov. Disord."},{"key":"1163_CR207","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/mds.27345","volume":"33","author":"I Litvan","year":"2018","unstructured":"Litvan, I., Kieburtz, K., Troster, A. I. & Aarsland, D. Strengths and challenges in conducting clinical trials in Parkinson\u2019s disease mild cognitive impairment. Mov. Disord. 33, 520\u2013527 (2018).","journal-title":"Mov. Disord."},{"key":"1163_CR208","first-page":"82","volume":"32","author":"YS Wang","year":"2024","unstructured":"Wang, Y. S., Ma, H. & Zhang, K. Clinical effect of high-frequency repetitive transcranial magnetic stimulation in the treatment of cognitive dysfunction in patients with Parkinson\u2019s disease. Clin. Res. 32, 82\u201385 (2024).","journal-title":"Clin. Res."},{"key":"1163_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64196-0","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Ding, Y. & Guo, C. Assessment of noninvasive brain stimulation interventions in Parkinson\u2019s disease: a systematic review and network meta-analysis. Sci. Rep. 14, 14219 (2024).","journal-title":"Sci. Rep."},{"key":"1163_CR210","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.brs.2020.04.010","volume":"13","author":"J Gratwicke","year":"2020","unstructured":"Gratwicke, J. et al. Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: a randomised clinical trial. Brain Stimul. 13, 1031\u20131039 (2020).","journal-title":"Brain Stimul."},{"key":"1163_CR211","doi-asserted-by":"publisher","DOI":"10.1162\/imag_a_00067","author":"RA Crockett","year":"2024","unstructured":"Crockett, R. A. et al. An individualized tractography pipeline for the nucleus basalis of Meynert lateral tract. Imaging Neurosci. https:\/\/doi.org\/10.1162\/imag_a_00067 (2024).","journal-title":"Imaging Neurosci."},{"key":"1163_CR212","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41582-023-00802-5","volume":"19","author":"K Ray Chaudhuri","year":"2023","unstructured":"Ray Chaudhuri, K., Leta, V., Bannister, K., Brooks, D. J. & Svenningsson, P. The noradrenergic subtype of Parkinson disease: from animal models to clinical practice. Nat. Rev. Neurol. 19, 333\u2013345 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1163_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107086","volume":"127","author":"S Kim","year":"2024","unstructured":"Kim, S., Woo, K. A., Choi, H., Shin, J. H. & Kim, H. J. Monoaminergic degeneration, cognition, and autonomic symptom trajectory in early Parkinson\u2019s disease. Parkinsonism Relat. Disord. 127, 107086 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR214","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172460","volume":"134","author":"DS Goldstein","year":"2024","unstructured":"Goldstein, D. S. et al. Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases. J. Clin. Invest. 134, e172460 (2024).","journal-title":"J. Clin. Invest."},{"key":"1163_CR215","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00897","volume":"11","author":"K Longardner","year":"2020","unstructured":"Longardner, K., Bayram, E. & Litvan, I. Orthostatic hypotension is associated with cognitive decline in Parkinson disease. Front. Neurol. 11, 897 (2020).","journal-title":"Front. Neurol."},{"key":"1163_CR216","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10286-021-00841-2","volume":"32","author":"SH Kang","year":"2022","unstructured":"Kang, S. H., Chung, S. J., Lee, J. & Koh, S. B. Independent effect of neurogenic orthostatic hypotension on mild cognitive impairment in Parkinson\u2019s disease. Clin. Auton. Res. 32, 43\u201350 (2022).","journal-title":"Clin. Auton. Res."},{"key":"1163_CR217","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10072-022-06537-3","volume":"44","author":"D Loureiro","year":"2023","unstructured":"Loureiro, D. et al. A systematic review and meta-analysis on the association between orthostatic hypotension and mild cognitive impairment and dementia in Parkinson\u2019s disease. Neurol. Sci. 44, 1211\u20131222 (2023).","journal-title":"Neurol. Sci."},{"key":"1163_CR218","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/mdc3.14179","volume":"11","author":"YH Hiorth","year":"2024","unstructured":"Hiorth, Y. H., Schulz, J., Pedersen, K. F., Tysnes, O. B. & Alves, G. Orthostatic hypotension and risk of mild cognitive impairment and dementia in Parkinson\u2019s disease. Mov. Disord. Clin. Pract. 11, 1365\u20131372 (2024).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1163_CR219","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.autneu.2011.02.004","volume":"161","author":"R Freeman","year":"2011","unstructured":"Freeman, R. et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton. Neurosci. 161, 46\u201348 (2011).","journal-title":"Auton. Neurosci."},{"key":"1163_CR220","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.927009","volume":"14","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Impaired dynamic cerebral autoregulation: a potential mechanism of orthostatic hypotension and dementia in Parkinson\u2019s disease. Front. Aging Neurosci. 14, 927009 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1163_CR221","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/mdc3.13003","volume":"7","author":"M Dadar","year":"2020","unstructured":"Dadar, M. et al. White matter hyperintensities mediate impact of dysautonomia on cognition in Parkinson\u2019s disease. Mov. Disord. Clin. Pract. 7, 639\u2013647 (2020).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1163_CR222","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ana.25923","volume":"89","author":"AJ Espay","year":"2021","unstructured":"Espay, A. J. et al. Rivastigmine in Parkinson\u2019s disease dementia with orthostatic hypotension. Ann. Neurol. 89, 91\u201398 (2021).","journal-title":"Ann. Neurol."},{"key":"1163_CR223","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/jnnp-2016-314123","volume":"87","author":"SJ Udow","year":"2016","unstructured":"Udow, S. J. et al. \u2018Under pressure\u2019: is there a link between orthostatic hypotension and cognitive impairment in \u03b1-synucleinopathies? J. Neurol. Neurosurg. Psychiatry 87, 1311\u20131321 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1163_CR224","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mds.26632","volume":"31","author":"C McDonald","year":"2016","unstructured":"McDonald, C., Newton, J. L. & Burn, D. J. Orthostatic hypotension and cognitive impairment in Parkinson\u2019s disease: causation or association? Mov. Disord. 31, 937\u2013946 (2016).","journal-title":"Mov. Disord."},{"key":"1163_CR225","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003748","volume":"4","author":"JJ Iliff","year":"2012","unstructured":"Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2. Sci. Transl. Med. 4, 147ra111 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1163_CR226","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.tins.2020.04.003","volume":"43","author":"H Mestre","year":"2020","unstructured":"Mestre, H., Mori, Y. & Nedergaard, M. The Brain\u2019s glymphatic system: current controversies. Trends Neurosci. 43, 458\u2013466 (2020).","journal-title":"Trends Neurosci."},{"key":"1163_CR227","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00293-2","volume":"11","author":"DM Lopes","year":"2022","unstructured":"Lopes, D. M., Llewellyn, S. K. & Harrison, I. F. Propagation of tau and \u03b1-synuclein in the brain: therapeutic potential of the glymphatic system. Transl. Neurodegener. 11, 19 (2022).","journal-title":"Transl. Neurodegener."},{"key":"1163_CR228","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-05911-5","volume":"7","author":"E Licastro","year":"2024","unstructured":"Licastro, E. et al. Glymphatic and lymphatic communication with systemic responses during physiological and pathological conditions in the central nervous system. Commun. Biol. 7, 229 (2024).","journal-title":"Commun. Biol."},{"key":"1163_CR229","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112928","volume":"23","author":"A Scott-Massey","year":"2022","unstructured":"Scott-Massey, A. et al. Glymphatic system dysfunction and sleep disturbance may contribute to the pathogenesis and progression of Parkinson\u2019s disease. Int. J. Mol. Sci. 23, 12928 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1163_CR230","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1241224","volume":"342","author":"L Xie","year":"2013","unstructured":"Xie, L. et al. Sleep drives metabolite clearance from the adult brain. Science 342, 373\u2013377 (2013).","journal-title":"Science"},{"key":"1163_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2023.101759","volume":"68","author":"G Maggi","year":"2023","unstructured":"Maggi, G., Vitale, C., Cerciello, F. & Santangelo, G. Sleep and wakefulness disturbances in Parkinson\u2019s disease: a meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. Sleep. Med. Rev. 68, 101759 (2023).","journal-title":"Sleep. Med. Rev."},{"key":"1163_CR232","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav5447","volume":"5","author":"LM Hablitz","year":"2019","unstructured":"Hablitz, L. M. et al. Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci. Adv. 5, eaav5447 (2019).","journal-title":"Sci. Adv."},{"key":"1163_CR233","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae233","volume":"48","author":"L Meinhold","year":"2025","unstructured":"Meinhold, L. et al. T2 MRI visible perivascular spaces in Parkinson\u2019s disease: clinical significance and association with polysomnography measured sleep. Sleep 48, zsae233 (2025).","journal-title":"Sleep"},{"key":"1163_CR234","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00316-9","volume":"8","author":"X Si","year":"2022","unstructured":"Si, X. et al. Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 54 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR235","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00962-9","volume":"11","author":"X Ma","year":"2025","unstructured":"Ma, X. et al. Parkinson\u2019s disease with possible REM sleep behavior disorder correlated with more severe glymphatic system dysfunction. NPJ Parkinsons Dis. 11, 82 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR236","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae251","volume":"48","author":"J Nepozitek","year":"2025","unstructured":"Nepozitek, J., Dusek, P. & Sonka, K. Glymphatic system, sleep, and Parkinson\u2019s disease: interconnections, research opportunities, and potential for disease modification. Sleep 48, zsae25 (2025).","journal-title":"Sleep"},{"key":"1163_CR237","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1251755","volume":"15","author":"M Buongiorno","year":"2023","unstructured":"Buongiorno, M. et al. Altered sleep and neurovascular dysfunction in \u03b1-synucleinopathies: the perfect storm for glymphatic failure. Front. Aging Neurosci. 15, 1251755 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"1163_CR238","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-019-0147-y","volume":"8","author":"W Zou","year":"2019","unstructured":"Zou, W. et al. Blocking meningeal lymphatic drainage aggravates Parkinson\u2019s disease-like pathology in mice overexpressing mutated \u03b1-synuclein. Transl. Neurodegener. 8, 7 (2019).","journal-title":"Transl. Neurodegener."},{"key":"1163_CR239","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1007\/s12031-021-01836-4","volume":"71","author":"H Cui","year":"2021","unstructured":"Cui, H. et al. Decreased AQP4 expression aggravates \u03b1-synuclein pathology in Parkinson\u2019s disease mice, possibly via impaired glymphatic clearance. J. Mol. Neurosci. 71, 2500\u20132513 (2021).","journal-title":"J. Mol. Neurosci."},{"key":"1163_CR240","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s12035-023-03212-2","volume":"60","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Interaction between the glymphatic system and \u03b1-synuclein in Parkinson\u2019s disease. Mol. Neurobiol. 60, 2209\u20132222 (2023).","journal-title":"Mol. Neurobiol."},{"key":"1163_CR241","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bpa.12369","volume":"27","author":"A Hoshi","year":"2017","unstructured":"Hoshi, A. et al. Expression of aquaporin 1 and aquaporin 4 in the temporal neocortex of patients with Parkinson\u2019s disease. Brain Pathol. 27, 160\u2013168 (2017).","journal-title":"Brain Pathol."},{"key":"1163_CR242","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41591-020-01198-1","volume":"27","author":"XB Ding","year":"2021","unstructured":"Ding, X. B. et al. Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson\u2019s disease. Nat. Med. 27, 411\u2013418 (2021).","journal-title":"Nat. Med."},{"key":"1163_CR243","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/mds.27798","volume":"34","author":"YW Park","year":"2019","unstructured":"Park, Y. W. et al. Magnetic resonance imaging-visible perivascular spaces in basal ganglia predict cognitive decline in Parkinson\u2019s disease. Mov. Disord. 34, 1672\u20131679 (2019).","journal-title":"Mov. Disord."},{"key":"1163_CR244","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/mds.28473","volume":"36","author":"EK Donahue","year":"2021","unstructured":"Donahue, E. K. et al. Global and regional changes in perivascular space in idiopathic and familial Parkinson\u2019s disease. Mov. Disord. 36, 1126\u20131136 (2021).","journal-title":"Mov. Disord."},{"key":"1163_CR245","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11682-023-00811-4","volume":"18","author":"EK Donahue","year":"2024","unstructured":"Donahue, E. K. et al. Increased perivascular space volume in white matter and basal ganglia is associated with cognition in Parkinson\u2019s disease. Brain Imaging Behav. 18, 57\u201365 (2024).","journal-title":"Brain Imaging Behav."},{"key":"1163_CR246","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.29908","volume":"39","author":"KH Wood","year":"2024","unstructured":"Wood, K. H. et al. Diffusion tensor imaging-along the perivascular-space index is associated with disease progression in Parkinson\u2019s disease. Mov. Disord. 39, 1504\u20131513 (2024).","journal-title":"Mov. Disord."},{"key":"1163_CR247","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ana.26729","volume":"94","author":"P He","year":"2023","unstructured":"He, P. et al. The association of the glymphatic function with Parkinson\u2019s disease symptoms: neuroimaging evidence from longitudinal and cross-sectional studies. Ann. Neurol. 94, 672\u2013683 (2023).","journal-title":"Ann. Neurol."},{"key":"1163_CR248","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.parkreldis.2022.01.002","volume":"95","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Perivascular space in Parkinson\u2019s disease: association with CSF amyloid\/tau and cognitive decline. Parkinsonism Relat. Disord. 95, 70\u201376 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR249","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3607","volume":"14","author":"RP Foreman","year":"2024","unstructured":"Foreman, R. P. et al. High baseline perivascular space volume in basal ganglia is associated with attention and executive function decline in Parkinson\u2019s disease. Brain Behav. 14, e3607 (2024).","journal-title":"Brain Behav."},{"key":"1163_CR250","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16521","volume":"31","author":"C Zhou","year":"2024","unstructured":"Zhou, C. et al. Glymphatic system dysfunction and risk of clinical milestones in patients with Parkinson disease. Eur. J. Neurol. 31, e16521 (2024).","journal-title":"Eur. J. Neurol."},{"key":"1163_CR251","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/WNR.0000000000001781","volume":"33","author":"EK Donahue","year":"2022","unstructured":"Donahue, E. K. et al. Magnetic resonance spectroscopy shows associations between neurometabolite levels and perivascular space volume in Parkinson\u2019s disease: a pilot and feasibility study. Neuroreport 33, 291\u2013296 (2022).","journal-title":"Neuroreport"},{"key":"1163_CR252","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4103\/NRR.NRR-D-24-00764","volume":"21","author":"X Lian","year":"2026","unstructured":"Lian, X. et al. Targeting the glymphatic system to promote \u03b1-synuclein clearance: a novel therapeutic strategy for Parkinson\u2019s disease. Neural Regen. Res. 21, 233\u2013247 (2026).","journal-title":"Neural Regen. Res."},{"key":"1163_CR253","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01111-4","volume":"21","author":"S Tinaz","year":"2021","unstructured":"Tinaz, S. Functional connectome in Parkinson\u2019s disease and parkinsonism. Curr. Neurol. Neurosci. Rep. 21, 24 (2021).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"1163_CR254","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00234-020-02378-z","volume":"62","author":"Y Hou","year":"2020","unstructured":"Hou, Y. et al. Primary disruption of the default mode network subsystems in drug-naive Parkinson\u2019s disease with mild cognitive impairments. Neuroradiology 62, 685\u2013692 (2020).","journal-title":"Neuroradiology"},{"key":"1163_CR255","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.2147\/IJGM.S300422","volume":"14","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Functional connectivity in Parkinson\u2019s disease patients with mild cognitive impairment. Int. J. Gen. Med. 14, 2623\u20132630 (2021).","journal-title":"Int. J. Gen. Med."},{"key":"1163_CR256","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1093\/cercor\/bhab148","volume":"31","author":"KA Schindlbeck","year":"2021","unstructured":"Schindlbeck, K. A. et al. Cognition-related functional topographies in Parkinson\u2019s disease: localized loss of the ventral default mode network. Cereb. Cortex 31, 5139\u20135150 (2021).","journal-title":"Cereb. Cortex"},{"key":"1163_CR257","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02360-z","volume":"21","author":"Y Hou","year":"2021","unstructured":"Hou, Y. et al. Different resting-state network disruptions in newly diagnosed drug-naive Parkinson\u2019s disease patients with mild cognitive impairment. BMC Neurol. 21, 327 (2021).","journal-title":"BMC Neurol."},{"key":"1163_CR258","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.parkreldis.2021.01.002","volume":"83","author":"P Zarifkar","year":"2021","unstructured":"Zarifkar, P. et al. Cognitive impairment in Parkinson\u2019s disease is associated with default mode network subsystem connectivity and cerebrospinal fluid abeta. Parkinsonism Relat. Disord. 83, 71\u201378 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR259","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.905121","volume":"16","author":"L Chen","year":"2022","unstructured":"Chen, L., Huang, T., Ma, D. & Chen, Y. C. Altered default mode network functional connectivity in Parkinson\u2019s disease: a resting-state functional magnetic resonance imaging study. Front. Neurosci. 16, 905121 (2022).","journal-title":"Front. Neurosci."},{"key":"1163_CR260","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1002\/hbm.25393","volume":"42","author":"MC Ruppert","year":"2021","unstructured":"Ruppert, M. C. et al. The default mode network and cognition in Parkinson\u2019s disease: a multimodal resting-state network approach. Hum. Brain Mapp. 42, 2623\u20132641 (2021).","journal-title":"Hum. Brain Mapp."},{"key":"1163_CR261","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02478-3","volume":"4","author":"AD Cascone","year":"2021","unstructured":"Cascone, A. D., Langella, S., Sklerov, M. & Dayan, E. Frontoparietal network resilience is associated with protection against cognitive decline in Parkinson\u2019s disease. Commun. Biol. 4, 1021 (2021).","journal-title":"Commun. Biol."},{"key":"1163_CR262","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3395","volume":"14","author":"F Hajebrahimi","year":"2024","unstructured":"Hajebrahimi, F. et al. Functional neural networks stratify Parkinson\u2019s disease patients across the spectrum of cognitive impairment. Brain Behav. 14, e3395 (2024).","journal-title":"Brain Behav."},{"key":"1163_CR263","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s11682-021-00543-3","volume":"16","author":"I Aracil-Bola\u00f1os","year":"2022","unstructured":"Aracil-Bola\u00f1os, I. et al. Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson\u2019s disease mild cognitive impairment. Brain Imaging Behav. 16, 761\u2013772 (2022).","journal-title":"Brain Imaging Behav."},{"key":"1163_CR264","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2024.103610","volume":"42","author":"BE Yeager","year":"2024","unstructured":"Yeager, B. E., Twedt, H. P., Bruss, J., Schultz, J. & Narayanan, N. S. Cortical and subcortical functional connectivity and cognitive impairment in Parkinson\u2019s disease. Neuroimage Clin. 42, 103610 (2024).","journal-title":"Neuroimage Clin."},{"key":"1163_CR265","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/ene.13886","volume":"26","author":"SJ Chung","year":"2019","unstructured":"Chung, S. J. et al. Clinical relevance of amnestic versus non-amnestic mild cognitive impairment subtyping in Parkinson\u2019s disease. Eur. J. Neurol. 26, 766\u2013773 (2019).","journal-title":"Eur. J. Neurol."},{"key":"1163_CR266","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s00415-018-8755-5","volume":"265","author":"K Kawabata","year":"2018","unstructured":"Kawabata, K. et al. Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson\u2019s disease. J. Neurol. 265, 688\u2013700 (2018).","journal-title":"J. Neurol."},{"key":"1163_CR267","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75008-6","volume":"10","author":"N Wright","year":"2020","unstructured":"Wright, N. et al. Elevated caudate connectivity in cognitively normal Parkinson\u2019s disease patients. Sci. Rep. 10, 17978 (2020).","journal-title":"Sci. Rep."},{"key":"1163_CR268","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000526377","volume":"22","author":"LE Llewelyn","year":"2022","unstructured":"Llewelyn, L. E., Kornisch, M., Park, H. & Ikuta, T. Hippocampal functional connectivity in Parkinson\u2019s disease. Neurodegener. Dis. 22, 29\u201333 (2022).","journal-title":"Neurodegener. Dis."},{"key":"1163_CR269","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11040433","volume":"11","author":"G Carli","year":"2021","unstructured":"Carli, G., Tondo, G., Boccalini, C. & Perani, D. Brain molecular connectivity in neurodegenerative conditions. Brain Sci. 11, 433 (2021).","journal-title":"Brain Sci."},{"key":"1163_CR270","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3454","volume":"14","author":"D Pourzinal","year":"2024","unstructured":"Pourzinal, D. et al. Hippocampal resting-state connectivity is associated with posterior-cortical cognitive impairment in Parkinson\u2019s disease. Brain Behav. 14, e3454 (2024).","journal-title":"Brain Behav."},{"key":"1163_CR271","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac165","volume":"4","author":"AS Kulkarni","year":"2022","unstructured":"Kulkarni, A. S., Burns, M. R., Brundin, P. & Wesson, D. W. Linking \u03b1-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson\u2019s disease. Brain Commun. 4, fcac165 (2022).","journal-title":"Brain Commun."},{"key":"1163_CR272","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03050-6","volume":"21","author":"P Garg","year":"2024","unstructured":"Garg, P. et al. Human serum-derived \u03b1-synuclein auto-antibodies mediate NMDA receptor-dependent degeneration of CNS neurons. J. Neuroinflammation 21, 62 (2024).","journal-title":"J. Neuroinflammation"},{"key":"1163_CR273","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.868790","volume":"15","author":"K Leite","year":"2022","unstructured":"Leite, K. et al. \u03b1-Synuclein impacts on intrinsic neuronal network activity through reduced levels of cyclic AMP and diminished numbers of active presynaptic terminals. Front. Mol. Neurosci. 15, 868790 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"1163_CR274","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12071411","volume":"12","author":"BM Pizarro-Galleguillos","year":"2023","unstructured":"Pizarro-Galleguillos, B. M., Kunert, L., Bruggemann, N. & Prasuhn, J. Neuroinflammation and mitochondrial dysfunction in Parkinson\u2019s disease: connecting neuroimaging with pathophysiology. Antioxidants 12, 1411 (2023).","journal-title":"Antioxidants"},{"key":"1163_CR275","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/hbm.23260","volume":"38","author":"A Vo","year":"2017","unstructured":"Vo, A. et al. Parkinson\u2019s disease-related network topographies characterized with resting state functional MRI. Hum. Brain Mapp. 38, 617\u2013630 (2017).","journal-title":"Hum. Brain Mapp."},{"key":"1163_CR276","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/mds.29565","volume":"38","author":"SH Jeong","year":"2023","unstructured":"Jeong, S. H. et al. Differential implications of cerebral hypoperfusion and hyperperfusion in Parkinson\u2019s disease. Mov. Disord. 38, 1881\u20131890 (2023).","journal-title":"Mov. Disord."},{"key":"1163_CR277","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1093\/cercor\/bhab520","volume":"32","author":"X Suo","year":"2022","unstructured":"Suo, X. et al. Brain functional network abnormalities in Parkinson\u2019s disease with mild cognitive impairment. Cereb. Cortex 32, 4857\u20134868 (2022).","journal-title":"Cereb. Cortex"},{"key":"1163_CR278","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11065-022-09559-y","volume":"33","author":"C Zuo","year":"2023","unstructured":"Zuo, C. et al. Global alterations of whole brain structural connectome in Parkinson\u2019s disease: a meta-analysis. Neuropsychol. Rev. 33, 783\u2013802 (2023).","journal-title":"Neuropsychol. Rev."},{"key":"1163_CR279","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s11682-024-00860-3","volume":"18","author":"V Galvez","year":"2024","unstructured":"Galvez, V., Romero-Rebollar, C., Estudillo-Guerra, M. A. & Fernandez-Ruiz, J. Resting-state networks and their relationship with MoCA performance in PD patients. Brain Imaging Behav. 18, 612\u2013621 (2024).","journal-title":"Brain Imaging Behav."},{"key":"1163_CR280","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1002\/hbm.26316","volume":"44","author":"C Wu","year":"2023","unstructured":"Wu, C. et al. Normalization effect of dopamine replacement therapy on brain functional connectome in Parkinson\u2019s disease. Hum. Brain Mapp. 44, 3845\u20133858 (2023).","journal-title":"Hum. Brain Mapp."},{"key":"1163_CR281","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78642-6","volume":"14","author":"K Kinugawa","year":"2024","unstructured":"Kinugawa, K., Mano, T. & Sugie, K. Changes in brain functional connectivity between on and off states and their relationship with cognitive impairment in Parkinson\u2019s disease. Sci. Rep. 14, 27333 (2024).","journal-title":"Sci. Rep."},{"key":"1163_CR282","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11910-024-01365-8","volume":"24","author":"N Piramide","year":"2024","unstructured":"Piramide, N., De Micco, R., Siciliano, M., Silvestro, M. & Tessitore, A. Resting-state functional MRI approaches to Parkinsonisms and related dementia. Curr. Neurol. Neurosci. Rep. 24, 461\u2013477 (2024).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"1163_CR283","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00117","volume":"13","author":"XN Zuo","year":"2019","unstructured":"Zuo, X. N., Biswal, B. B. & Poldrack, R. A. Editorial: reliability and reproducibility in functional connectomics. Front. Neurosci. 13, 117 (2019).","journal-title":"Front. Neurosci."},{"key":"1163_CR284","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1163_CR285","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer, A. et al. \u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid \u2014 a systematic review and meta-analysis. Mov. Disord. Clin. Pract. 10, 737\u2013747 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1163_CR286","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.parkreldis.2022.10.007","volume":"104","author":"D Yoo","year":"2022","unstructured":"Yoo, D. et al. Diagnostic value of \u03b1-synuclein seeding amplification assays in \u03b1-synucleinopathies: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 104, 99\u2013109 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR287","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1163_CR288","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00401-025-02853-y","volume":"149","author":"AM Bernhardt","year":"2025","unstructured":"Bernhardt, A. M. et al. A quantitative Lewy-fold-specific \u03b1-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease. Acta Neuropathologica 149, 20 (2025).","journal-title":"Acta Neuropathologica"},{"key":"1163_CR289","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/mds.29683","volume":"39","author":"F Cardoso","year":"2024","unstructured":"Cardoso, F. et al. A statement of the mds on biological definition, staging, and classification of Parkinson\u2019s disease. Mov. Disord. 39, 259\u2013266 (2024).","journal-title":"Mov. Disord."},{"key":"1163_CR290","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","volume":"36","author":"WW Aamodt","year":"2021","unstructured":"Aamodt, W. W. et al. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov. Disord. 36, 2945\u20132950 (2021).","journal-title":"Mov. Disord."},{"key":"1163_CR291","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00384-x","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu, L. et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 154 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR292","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.28056","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche, S. et al. CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories. Mov. Disord. 35, 1138\u20131144 (2020).","journal-title":"Mov. Disord."},{"key":"1163_CR293","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application. Nat. Rev. Neurol. 20, 269\u2013287 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1163_CR294","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/mds.28909","volume":"37","author":"C Buhmann","year":"2022","unstructured":"Buhmann, C. et al. Age-adjusted serum neurofilament predicts cognitive decline in Parkinson\u2019s disease (MARK-PD). Mov. Disord. 37, 435\u2013436 (2022).","journal-title":"Mov. Disord."},{"key":"1163_CR295","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s007020200027","volume":"109","author":"KA Jellinger","year":"2002","unstructured":"Jellinger, K. A., Seppi, K., Wenning, G. K. & Poewe, W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson\u2019s disease. J. Neural Transm. 109, 329\u2013339 (2002).","journal-title":"J. Neural Transm."},{"key":"1163_CR296","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","volume":"72","author":"DJ Irwin","year":"2012","unstructured":"Irwin, D. J. et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587\u2013598 (2012).","journal-title":"Ann. Neurol."},{"key":"1163_CR297","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","volume":"23","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh, M. N. et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis. Associated Disord. 23, 295\u2013297 (2009).","journal-title":"Alzheimer Dis. Associated Disord."},{"key":"1163_CR298","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","volume":"69","author":"PT Kotzbauer","year":"2012","unstructured":"Kotzbauer, P. T. et al. Pathologic accumulation of \u03b1-Synuclein and A\u03b2 in Parkinson disease patients with dementia. Arch. Neurol. 69, 1326\u20131331 (2012).","journal-title":"Arch. Neurol."},{"key":"1163_CR299","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.25392","volume":"85","author":"D Coughlin","year":"2019","unstructured":"Coughlin, D. et al. Cognitive and pathological influences of tau pathology in lewy body disorders. Ann. Neurol. 85, 259\u2013271 (2019).","journal-title":"Ann. Neurol."},{"key":"1163_CR300","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin, D. J. et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 16, 55\u201365 (2017).","journal-title":"Lancet Neurol."},{"key":"1163_CR301","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","volume":"84","author":"S Hall","year":"2015","unstructured":"Hall, S. et al. CSF biomarkers and clinical progression of Parkinson disease. Neurology 84, 57\u201363 (2015).","journal-title":"Neurology"},{"key":"1163_CR302","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00415-021-10402-2","volume":"269","author":"RI Orad","year":"2022","unstructured":"Orad, R. I. & Shiner, T. Differentiating dementia with Lewy bodies from Alzheimer\u2019s disease and Parkinson\u2019s disease dementia: an update on imaging modalities. J. Neurol. 269, 639\u2013653 (2022).","journal-title":"J. Neurol."},{"key":"1163_CR303","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.25811","volume":"88","author":"DJ Irwin","year":"2020","unstructured":"Irwin, D. J. et al. Evolution of Alzheimer\u2019s disease cerebrospinal fluid biomarkers in early Parkinson\u2019s Disease. Ann. Neurol. 88, 574\u2013587 (2020).","journal-title":"Ann. Neurol."},{"key":"1163_CR304","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.nbd.2019.02.023","volume":"127","author":"M Shahid","year":"2019","unstructured":"Shahid, M. et al. An increased rate of longitudinal cognitive decline is observed in Parkinson\u2019s disease patients with low CSF A\u03b242 and an APOE \u03b54 allele. Neurobiol. Dis. 127, 278\u2013286 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1163_CR305","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.parkreldis.2022.02.006","volume":"95","author":"Q Devignes","year":"2022","unstructured":"Devignes, Q., Lopes, R. & Dujardin, K. Neuroimaging outcomes associated with mild cognitive impairment subtypes in Parkinson\u2019s disease: a systematic review. Parkinsonism Relat. Disord. 95, 122\u2013137 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1163_CR306","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14789","volume":"30","author":"Y Jian","year":"2024","unstructured":"Jian, Y. et al. Prediction of cognitive decline in Parkinson\u2019s disease based on MRI radiomics and clinical features: a multicenter study. CNS Neurosci. Ther. 30, e14789 (2024).","journal-title":"CNS Neurosci. Ther."},{"key":"1163_CR307","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00566-1","volume":"9","author":"CJ Park","year":"2023","unstructured":"Park, C. J. et al. An interpretable multiparametric radiomics model of basal ganglia to predict dementia conversion in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 127 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR308","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.clinph.2015.10.030","volume":"127","author":"M Hata","year":"2016","unstructured":"Hata, M. et al. Functional connectivity assessed by resting state EEG correlates with cognitive decline of Alzheimer\u2019s disease \u2014 an eLORETA study. Clin. Neurophysiol. 127, 1269\u20131278 (2016).","journal-title":"Clin. Neurophysiol."},{"key":"1163_CR309","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jns.2009.08.028","volume":"289","author":"CJ Stam","year":"2010","unstructured":"Stam, C. J. Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders. J. Neurol. Sci. 289, 128\u2013134 (2010).","journal-title":"J. Neurol. Sci."},{"key":"1163_CR310","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/mds.29026","volume":"37","author":"S Yassine","year":"2022","unstructured":"Yassine, S. et al. Functional brain dysconnectivity in Parkinson\u2019s disease: a 5-year longitudinal study. Mov. Disord. 37, 1444\u20131453 (2022).","journal-title":"Mov. Disord."},{"key":"1163_CR311","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/mds.29451","volume":"38","author":"S Yassine","year":"2023","unstructured":"Yassine, S. et al. Identification of Parkinson\u2019s disease subtypes from resting-state electroencephalography. Mov. Disord. 38, 1451\u20131460 (2023).","journal-title":"Mov. Disord."},{"key":"1163_CR312","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ana.27035","volume":"96","author":"A Puig-Davi","year":"2024","unstructured":"Puig-Davi, A. et al. Prediction of cognitive heterogeneity in Parkinson\u2019s disease: a 4-year longitudinal study using clinical, neuroimaging, biological and electrophysiological biomarkers. Ann. Neurol. 96, 981\u2013993 (2024).","journal-title":"Ann. Neurol."},{"key":"1163_CR313","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac040","volume":"4","author":"D Backstrom","year":"2022","unstructured":"Backstrom, D. et al. Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. Brain Commun. 4, fcac040 (2022).","journal-title":"Brain Commun."},{"key":"1163_CR314","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12081048","volume":"12","author":"PH Chen","year":"2022","unstructured":"Chen, P. H., Hou, T. Y., Cheng, F. Y. & Shaw, J. S. Prediction of cognitive degeneration in Parkinson\u2019s disease patients using a machine learning method. Brain Sci. 12, 1048 (2022).","journal-title":"Brain Sci."},{"key":"1163_CR315","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-37644-6","volume":"13","author":"H Almgren","year":"2023","unstructured":"Almgren, H. et al. Machine learning-based prediction of longitudinal cognitive decline in early Parkinson\u2019s disease using multimodal features. Sci. Rep. 13, 13193 (2023).","journal-title":"Sci. Rep."},{"key":"1163_CR316","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00409-5","volume":"8","author":"J Harvey","year":"2022","unstructured":"Harvey, J. et al. Machine learning-based prediction of cognitive outcomes in de novo Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 150 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR317","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-00121-2","volume":"6","author":"T Phongpreecha","year":"2020","unstructured":"Phongpreecha, T. et al. Multivariate prediction of dementia in Parkinson\u2019s disease. NPJ Parkinsons Dis. 6, 20 (2020).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR318","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00828-6","volume":"10","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y. et al. Multimodal neuroimaging-based prediction of Parkinson\u2019s disease with mild cognitive impairment using machine learning technique. NPJ Parkinsons Dis. 10, 218 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"1163_CR319","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/mds.30202","volume":"40","author":"D Weintraub","year":"2025","unstructured":"Weintraub, D. et al. Validation of the International Parkinson and Movement Disorder Society Non-Motor Symptoms Questionnaire (MDS-NMS-Q). Mov. Disord. 40, 1037\u20131046 (2025).","journal-title":"Mov. Disord."},{"key":"1163_CR320","doi-asserted-by":"publisher","unstructured":"Dias, S. B. et al. AI-driven motor and cognitive decline digital assessment for Parkinson\u2019s disease: a systematic review and meta-analysis. Preprint at SSRN https:\/\/doi.org\/10.2139\/ssrn.5142802 (2025).","DOI":"10.2139\/ssrn.5142802"},{"key":"1163_CR321","doi-asserted-by":"crossref","unstructured":"Craig, S. N., Dempster, M., Curran, D., Cuddihy, A. M. & Lyttle, N. A systematic review of the effectiveness of digital cognitive assessments of cognitive impairment in Parkinson\u2019s disease. Appl Neuropsychol Adult, 1\u201313 (2025).","DOI":"10.1080\/23279095.2025.2454983"},{"key":"1163_CR322","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30166","author":"O Bezdicek","year":"2025","unstructured":"Bezdicek, O. et al. Neuropsychological tests of memory, visuospatial, and language function in Parkinson\u2019s disease: review, critique, and recommendations. Mov. Disord. https:\/\/doi.org\/10.1002\/mds.30166 (2025).","journal-title":"Mov. Disord."},{"key":"1163_CR323","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre, M. et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov. Disord. 22, 1689\u20131707 (2007). quiz 1837.","journal-title":"Mov. Disord."},{"key":"1163_CR324","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14305","author":"J Kulisevsky","year":"2024","unstructured":"Kulisevsky, J. et al. A call for change: updating the operational definition for dementia in Parkinson\u2019s disease. Mov. Disord. Clin. Pract. https:\/\/doi.org\/10.1002\/mdc3.14305 (2024).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1163_CR325","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670\u2013676 (2008).","journal-title":"Neurology"},{"key":"1163_CR326","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00702-024-02796-w","volume":"131","author":"M Bode","year":"2024","unstructured":"Bode, M., Kalbe, E. & Liepelt-Scarfone, I. Cognition and activity of daily living function in people with Parkinson\u2019s disease. J. Neural Transm. 131, 1159\u20131186 (2024).","journal-title":"J. Neural Transm."},{"key":"1163_CR327","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/jmri.26892","volume":"51","author":"T Taoka","year":"2020","unstructured":"Taoka, T. & Naganawa, S. Glymphatic imaging using MRI. J. Magn. Reson. Imaging 51, 11\u201324 (2020).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1163_CR328","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mds.29708","volume":"39","author":"C Marras","year":"2024","unstructured":"Marras, C. et al. Transitioning from subtyping to precision medicine in Parkinson\u2019s disease: a purpose-driven approach. Mov. Disord. 39, 462\u2013471 (2024).","journal-title":"Mov. Disord."},{"key":"1163_CR329","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 (2023).","journal-title":"Nat. Commun."},{"key":"1163_CR330","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo, H. et al. Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron 112, 2540\u20132557.e8 (2024).","journal-title":"Neuron"},{"key":"1163_CR331","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2321633121","volume":"121","author":"K Liu","year":"2024","unstructured":"Liu, K. et al. Binding adaptability of chemical ligands to polymorphic \u03b1-synuclein amyloid fibrils. Proc. Natl Acad. Sci. USA 121, e2321633121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1163_CR332","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-022-00753-3","volume":"19","author":"M Perovnik","year":"2023","unstructured":"Perovnik, M., Rus, T., Schindlbeck, K. A. & Eidelberg, D. Functional brain networks in the evaluation of patients with neurodegenerative disorders. Nat. Rev. Neurol. 19, 73\u201390 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1163_CR333","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1442851","volume":"15","author":"C Wang","year":"2024","unstructured":"Wang, C. et al. Network disruption based on multi-modal EEG-MRI in \u03b1-synucleinopathies. Front. Neurol. 15, 1442851 (2024).","journal-title":"Front. Neurol."},{"key":"1163_CR334","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.3233\/JPD-230229","volume":"14","author":"CD Esper","year":"2024","unstructured":"Esper, C. D., Valdovinos, B. Y. & Schneider, R. B. The importance of digital health literacy in an evolving Parkinson\u2019s disease care system. J. Parkinsons Dis. 14, S181\u2013S189 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1163_CR335","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/13872877241298295","volume":"103","author":"E Angelopoulou","year":"2025","unstructured":"Angelopoulou, E. & Papageorgiou, S. G. Telemedicine in Alzheimer\u2019s disease and other dementias: where we are? J. Alzheimers Dis. 103, 3\u201318 (2025).","journal-title":"J. Alzheimers Dis."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01163-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T13:02:54Z","timestamp":1770210174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01163-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":335,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01163-x","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"30 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research of I.L. is supported by NIH grants U19AG063911, U01NS100610, 2P30AG062429, R01AG085029, U01NS112010, 5U01NS112010\/807745, U01NS100610, R25NS098999; U19 AG063911-1 and 1R21NS114764-01A1 and 2 P30 AG062429-06; the Michael J Fox Foundation, the Parkinson\u2019s Foundation, the Lewy Body Association, CurePSP, Roche, AbbVie, Lundbeck, EIP-Pharma, Alterity, Novartis and UCB. She is a member of the Scientific Advisory Board for the Rossy PSP Program at the University of Toronto, Aprinoia and Amydis (gratis). She is Chief Editor of\n                      Frontiers in Neurology\n                      . P.O., F.H.A. and N.O. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}